Brain Trust Accelerator Fund
Brain Trust Accelerator Fund is a venture capital firm focused on impact investing in brain-related diseases. The firm specializes in translational stage investments that address the diagnosis and treatment of these diseases. With a strong track record, Fund I has generated top-tier returns, benefiting up to ten million patients and delivering significant charitable contributions. The firm leverages scientific advancements and market opportunities to invest in early-stage, translational research, aiming to transform pioneering research into meaningful clinical benefits.
Industries
N/A
Nr. of Employees
small (1-50)
Brain Trust Accelerator Fund
800 Airport Boulevard, Suite 508, Burlingame, CA 94010
Portfolio
Focused on novel therapeutics for improving memory deficits. Acquired by SYGNIS Pharma AG in 2008.
#Biotechnology
Develops the BrainScope One system for brain injury assessment. Launched in 2017, targeting various market segments.
#Neuro-technology
Focused on treatments for central nervous system diseases. Acquired by Allergan in 2016 after successful clinical trials.
#Pharmaceuticals
Developed targeted treatment approaches for neurological disorders. Acquired by Minnetronix in 2013.
#Medical Devices
Developed blood-based tests for neurodegenerative diseases. Acquired by Myriad Genetics in 2011.
#Molecular Diagnostics
Developing small molecules targeting CB2 receptors to reduce neuroinflammation. Completed Phase 1a clinical trial.
#Biotechnology
Focused on novel therapeutics for improving memory deficits. Acquired by SYGNIS Pharma AG in 2008.
#Biotechnology
Develops the BrainScope One system for brain injury assessment. Launched in 2017, targeting various market segments.
#Neuro-technology
Focused on treatments for central nervous system diseases. Acquired by Allergan in 2016 after successful clinical trials.
#Pharmaceuticals
Developed targeted treatment approaches for neurological disorders. Acquired by Minnetronix in 2013.
#Medical Devices
Developed blood-based tests for neurodegenerative diseases. Acquired by Myriad Genetics in 2011.
#Molecular Diagnostics
Developing small molecules targeting CB2 receptors to reduce neuroinflammation. Completed Phase 1a clinical trial.
#Biotechnology